Purpose: To compare primary surgery and surgery after neoadjuvant chemotherapy (NCT) in locally advanced breast cancer (LABC) patients. Methods: Between January 2011 & December 2015, 112 patients with LABC were treated at KAAH & OC-Jeddah-KSA , Of whom 42 were treated by NCT followed by surgery either mastectomy or conservative surgery, then adjuvant chemotherapy and radiotherapy. The rest patients (70) were treated by primary surgery (mastectomy or conservative resection) and followed by adjuvant chemotherapy and radiotherapy. All patients received adjuvant antiestrogen. Patients were followed for a median duration of 33 months. Disease-free survival (DFS) and overall survival (OAS) were studied for all patients, compared between both groups and related to the extent of surgery and menopausal status. Results: median age was 46.5 years for all patients ; 48 years, and 46 years for NCT and primary surgery groups respectively. Median DFS was 15 months for all patients, 16 & 15 months for NCT and primary surgery groups. Median OAS was 24 months for all patients, 22 & 24 months for NCT and primary surgery groups. Difference in DFS & OAS were highly significant in favour of postmenopausal patients (p = 0.05 for DFS & p = 0.03 for OAS) while in primary surgery group the differences between pre and postmenopausal patients in DFS & OAS were statistically insignificant (p = 0.4). NCT followed by surgery group patients showed significant improvement in DFS & OAS in patients performed conservative surgery while in primary surgery group the difference was insignificant. Freedom of disease was seen in 28.6% in the NCT group and 37.1% for the primary surgery group. Conclusion: Surgery post-neoadjuvant chemotherapy neither prolongs DFS nor OAS in comparison with primary surgery followed by adjuvant chemotherapy. Postmenopausal patients f elt much better than premenopausal patients regarding DFS & OAS.
KeywordsAdjuvantBreastCancerNeoadjuvantSurgery
Singletary, S.E., Allred, C., Ashley, P., et al. (2002) Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. Journal of Clinical Oncology, 20, 3628-3636. https://doi.org/10.1200/JCO.2002.02.026
Simos, D., Clemons, M., Ginsburg, O.M. and Jacobs, C. (2014) Definition and Consequences of Locally Advanced Breast Cancer. Current Opinion in Supportive and Palliative Care, 8, 33-38
Cristofanilli, M., Buzdar, A.U. and Hortobágyi, G.N. (2003) Update on the Management of Inflammatory Breast Cancer. The Oncologist, 8, 141-148. https://doi.org/10.1634/theoncologist.8-2-141
Caudle, A.S. and Kuerer, H.M. (2014) Breast Conservation Therapy after Neoadjuvant Chemotherapy: Optimization of a Multimodality Approach. Journal of Surgical Oncology, 110, 32-36. https://doi.org/10.1002/jso.23595
Yalcin, B. (2013) Overview on Locally Advanced Breast Cancer: Defining, Epidemiology, and Overview on Neoadjuvant Therapy. Experimental Oncology, 35, 250-252.
Guilherme, F., Angotti, C., Cristovam, S., Lucas Faria, A., Maria, M., Joao, S., et al. (2017) Breast-Conserving Surgery in Locally Advanced Breast Cancer Submitted to Neoadjuvant Chemotherapy. Safety and Effectiveness Based on Ipsilateral Breast Tumor Recurrence and Long-Term Follow-Up. Clinics (Sao Paulo), 72, 134-142. https://doi.org/10.6061/clinics/2017(03)02
Ellis, G.K., Barlow, W.E., Gralow, J.R., Hortobagyi, G.N., Russell, C.A., Royce, M.E., et al. (2011) Phase III Comparison of Standard Doxorubicin and Cyclophosphamide versus Weekly Doxorubicin and Daily Oral Cyclophosphamide plus Granulocyte Colony-Stimulating Factor as Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012. Journal of Clinical Oncology, 29, 1014-1021. https://doi.org/10.1200/JCO.2009.27.6543
Mauri, D., Pavlidis, N. and Ioannidis, J.P. (2005) Neoadjuvant versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. Journal of the National Cancer Institute, 97, 188-194. https://doi.org/10.1093/jnci/dji021
Wang, H.C. and Lo, S.S. (1996) Future Prospects of Neoadjuvant Chemotherapy in the Treatment of Primary Breast Cancer. Seminars in Surgical Oncology, 12, 59-66. https://doi.org/10.1002/(SICI)1098-2388(199601/02)12:1 3.0.CO;2-5
Cuningham, J.D., Weiss, S.E., Ahmad, S., Bratton, J.H., Bleiweiss, I.J., Tarter, P.I. and Brower, S.T. (1998) The Efficacy of Neoadjuvant Chemotherapy Compared to Postoperative Therapy in the Treatment of Locally Advanced Breast Cancer. Cancer Investigation, 16, 86-96. https://doi.org/10.3109/07357909809039761
Karlesson, Y.A., Melstrom, P.O., Hatschek, T., Fornander, T.G., Soderberg, M., Bengtsson, Y.A., et al. (1998) Multimodality Treatment of 128 Patients with Locally Advanced Breast Carcinoma in the Era of Mammography Screening Using Standard Polychemotherapy with 5-FU Epirubicin and Cyclophosphamide, Prognostic and Therapeutic Implications. Cancer, 83, 936-947.
Singletary, S.E., Hortobagyi, G.N. and Kroll, S.S. (1995) Surgical and Medical Management of Local-Regional Treatment Failure in Advanced Primary Breast Cancer. Surgical Oncology Clinics of North America, 4, 671-684.
Ezzat, A.A., Ibrahim, E.M., Raja, M.A., Al-Sobhi, S., Rostom, A. and Stuart, R.K. (1999) Locally Advanced Breast Cancer in Saudi Arabia: High Frequency of Stage III in a Young Population. Medical Oncology, 16, 95-103. https://doi.org/10.1007/BF02785842
(2016) Cancer Incidence SA June 2016. Cancer Incidence Report, Saudi Arabia (2013-2015), Kingdom of Saudi Arabia, Ministry of Health, National Cancer Registry.
Lee, M.C. and Newman, L.A. (2007) Management of Patients with Locally Advanced Breast Cancer. Surgical Clinics of North America, 87, 379-398. https://doi.org/10.1016/j.suc.2007.01.012
Fisher, B., Bryant, J., Wol, A.N., Mamounas, E., Brown, A., Fisher, E.R., et al. (1998) Effect of Postoperative Chemotherapy on the Outcome of Women with Operable Breast Cancer. Journal of Clinical Oncology, 16, 2672-2685. https://doi.org/10.1200/JCO.1998.16.8.2672
Kuerer, H.M., Newman, L.A., Smith, T.L., Ames, F.C., Hunt, K.K., Buda, A.U., Hortobagyi, G.N. and Singletary, S.E. (1999) Clinical Course of Breast Cancer Patients with Complete Pathologic Primary Tumor and Axillary Lymph Nodes Response to Doxorubicin-Based Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 17, 468-496. https://doi.org/10.1200/JCO.1999.17.2.460
Crow, J.P., Gordon, N.H., Shank, R.R., Zollinger, R.M., Brumberg, D.J. and Shuck, J.M. (1994) Age Does Not Predict Cancer Outcome. The Archives of Surgery, 129, 483-496. https://doi.org/10.1001/archsurg.1994.01420290029004
Newman, L.A., Kuerer, H.M., Singh, G., Bucchloz, T.A., Hunt, K.K., Ames, F.C. and Singletary, S.E. (1998) Age-Related Difference in the Utilization and Impact of Multimodality Therapy on the Survival of Black Breast Cancer Patients. 34th Annual Meeting on Program/Proceedings of the American Society of Clinical Oncology, Vol. 17, May 1998.
Harris, J., Morrow, M. and Norton, L. (1997) Malignant Tumors of the Breast. In: DeVita, V.T., Hellman, S. and Rosenberg, S.A., Eds., Cancer Principles and Practice of Oncology, 5th Edition, Lippincott-Raven Publishers, Hagerstown, Ch. 36, Sec. 2.
Philiph, P.A., Penick, N.L., Vashanpey An, U., Simon, M.S., Lorusso, P., Chaplan, R., et al. (2000) Phase II Study of Doxorubicin, Docetaxel and 5 Fu (FAT) in Patients with Locally Advanced Breast Cancer. 36th Annual Meeting on Program/Proceedings of the American Society of Clinical Oncology, Vol. 19, May 2000.
Esteva, F.J., Rosoles, M.F., Esparazaguerre, L.T., Sahin, A.A., Soss, M.I., Booser, D.J., et al. (2000) Phase II Trial of Primary Chemotherapy with Docetaxel and Doxorubicin in Locally Advanced Breast Cancer-Clinical and Pathological Results. 36th Annual Meeting on Program/Proceedings of the American Society of Clinical Oncology, Vol. 19, May 2000.
Ellis, G.K., Green, S.J., Livingstone, G.T., Budd, S.E., Rivkin, J.K., Gandura, G.R. and Martino, S. (2000) Neoadjuvant Doxorubicin, Cyclophosphamide and G-CSF (AC+G) for Locally Advanced Breast Cancer (LABC) Southwest Oncology Phase II Trial. 36th Annual Meeting on Program/Proceedings of the American Society of Clinical Oncology, Vol. 19, May 2000.
Schwartz, G.F., Birchansky, C.A., Komamicky, L.T., Mansfield, C.M., Cantor, R.I., et al. (1994) Induction Chemotherapy Followed by Breast Conservation for Locally Advanced Carcinoma of the Breast. Cancer, 73, 362-369. https://doi.org/10.1002/1097-0142(19940115)73:2 3.0.CO;2-L
Murthy, S.M., Reid, S.E., Jonarden, S., Scenlon, C.F. and Khankar, J.D. (1999) Prevention of Breast Cancer Relapse by Neoadjuvant Chemotherapy-Status of the Mechanism. 36th Annual Meeting on Program/Proceedings of the American Society of Clinical Oncology, Vol. 18, May 1999.
Kent, A.L., Eaton, M., Marshal, N. and Humeniuk, V. (1995) Locally Advanced Breast Cancer Is Surgery Warranted Following, Chemotherapy. ANZ Journal of Surgery, 65, 229-332. https://doi.org/10.1111/j.1445-2197.1995.tb00617.x
Green, M.C., Buzdar, A.U., Smith, T., et al. (2005) Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared with Paclitaxel Once Every 3 Weeks. Journal of Clinical Oncology, 23, 5983-5992. https://doi.org/10.1200/JCO.2005.06.232
Taylor, M.E., Taylor, M.E., Perez, C.A. and Levitt, S.H. (1997) Breast: Locally Advanced (T3 and T4), Inflammatory and Recurrent Tumors. In: Perez, C.A. and Brady, L.W., Eds., Principles and Practice of Radiation Oncology, 3rd Edition, Lippincott-Raven Publishers, Hagerstown, Ch. 51.
Ellis, G.K., Green, S.J., Russell, C.A., et al. (2006) SWOG 0012, a Randomized Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel versus Weekly Doxorubicin and Daily Oral Cyclophosphamide plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer. Journal of Clinical Oncology, 24, LBA537.
Von Minckwitz, G., Raab, G., Caputo, A., et al. (2005) Doxorubicin with Cyclophosphamide Followed by Docetaxel Every 21 Days Compared with Doxorubicin and Docetaxel Every 14 Days as Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group. Journal of Clinical Oncology, 23, 2676-2685. https://doi.org/10.1200/JCO.2005.05.078
Papademetriou, K., Ardavanis, A. and Kountourakis, P. (2010) Neoadjuvant Therapy for Locally Advanced Breast Cancer: Focus on Chemotherapy and Biological targeted Treatments’ Armamentarium. Journal of Thoracic Disease, 2, 160-170.